Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Clovis Oncology nets $129mm in initial public offering

Executive Summary

Specialty cancer pharmaco Clovis Oncology Inc. has netted $129mm in its initial public offering of 10.7mm shares (including partial exercise of the overallotment) at $13, the low end of its $13-15 price range. The company initially planned to sell only 9.3mm shares. Existing stockholders, directors, and executive management have agreed to buy 4.3mm, or 43%, of the shares at the IPO price.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies